The application and analysis of low dose naloxone combined with ropivacaine in supraclavicular brachial plexus block

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17011219

Enrollment

Unknown

Registered

2017-04-22

Start date

2017-05-01

Completion date

Unknown

Last updated

2017-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brachial plexus block

Interventions

control group:ropivacaine(0.375%)29ml+saline(0.9%)1ml

treatment group:ropivacaine(0.375%)29ml+naloxone(10ug)1ml

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ASA I ~ III, 18-65 years of age, body mass index (BMI) of 20-35kg/m2, the operation is limited to the humerus below the middle of the upper limb (elbow, forearm, wrist, hand) operation time is controlled within 180mins, the patients who signed informed consent and agree to participate in the test

Exclusion criteria

Exclusion criteria: Long term use of opioids, alcohol abuse, hypertension, diabetes mellitus, congenital heart disease, kidney disease history, coagulation disorders, drugs and drug allergy related experimental amide, pregnant patients, suspected patients with neuropathy, and mental disorders can not match, the supraclavicular region had surgery / infection

Design outcomes

Primary

Measure	Time frame
duration of sensory block;	—

Secondary

Measure	Time frame
duration of motor block,;consumption of Opioids;Postoperative VAS score;Patient satisfaction;	—

Countries

China

Contacts

Public ContactShi Yisa

LanZhou University Second Hospital

shiys@lzu.com+86 13619334024

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026